Details of the Drug Combination

General Information of Drug Combination (ID: DCSNGT4)

Drug Combination Name
Tegafur Oxaliplatin
Indication
Disease Entry Status REF
Gastric Cancer Phase 3 [1]
Component Drugs Tegafur   DM31ZQM Oxaliplatin   DMQNWRD
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Tegafur
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [2]
Tegafur Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [6]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Metabolism [7]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [8]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Metabolism [8]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Tegafur Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Decreases Activity [9]
Dihydropyrimidine dehydrogenase (DPYD) OTWRF2NR DPYD_HUMAN Affects Response To Substance [10]
Cytidine deaminase (CDA) OT3HXP6N CDD_HUMAN Affects Response To Substance [10]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Response To Substance [11]
------------------------------------------------------------------------------------
Indication(s) of Oxaliplatin
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [3]
Appendiceal neoplasm N.A. Approved [3]
Cholangiocarcinoma 2C12.10 Approved [3]
Colon adenocarcinoma N.A. Approved [3]
Colorectal cancer 2B91.Z Approved [4]
Colorectal carcinoma N.A. Approved [3]
Endocrine gland neoplasm N.A. Approved [3]
Gallbladder carcinoma N.A. Approved [3]
Metastasis from malignant tumor of colon N.A. Approved [3]
Nasopharyngeal carcinoma 2B6B Approved [3]
Peritoneal neoplasm N.A. Approved [3]
Rectal adenocarcinoma 2B92 Approved [3]
Rectal neoplasm N.A. Approved [3]
Rectum mucinous adenocarcinoma N.A. Approved [3]
Colon cancer 2B90.Z Investigative [3]
Gastric cancer 2B72 Investigative [3]
Oxaliplatin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [12]
------------------------------------------------------------------------------------
Oxaliplatin Interacts with 5 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [13]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [14]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [15]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [16]
High affinity copper uptake protein 1 (SLC31A1) DTP8L4F COPT1_HUMAN Substrate [17]
------------------------------------------------------------------------------------
Oxaliplatin Interacts with 12 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [18]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Metabolism [18]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Metabolism [18]
Cytochrome P450 1B1 (CYP1B1) DE9QHP6 CP1B1_HUMAN Metabolism [18]
Glutathione S-transferase pi (GSTP1) DEK6079 GSTP1_HUMAN Metabolism [19]
Glutathione S-transferase theta-1 (GSTT1) DE3PKUG GSTT1_HUMAN Metabolism [19]
Metallothionein-1A (MT1A) DE5ME8A MT1A_HUMAN Metabolism [19]
Metallothionein-2A (MT2A) DEFKGT7 MT2_HUMAN Metabolism [19]
Myeloperoxidase (MPO) DEA3U9Y PERM_HUMAN Metabolism [19]
Quinone reductase 1 (NQO1) DENP5RY NQO1_HUMAN Metabolism [19]
Superoxide dismutase 1 (SOD1) DEUTDON SODC_HUMAN Metabolism [19]
Glutathione S-transferase mu-1 (GSTM1) DEYZEJA GSTM1_HUMAN Metabolism [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DME(s)
Oxaliplatin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Protachykinin-1 (TAC1) OTM842YW TKN1_HUMAN Increases ADR [20]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05914610) Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Oxaliplatin FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7433).
5 [Thymidylate synthase gene promoter polymorphism in patients with advanced head and neck cancer treated by radio- and 5-fluorouracil chemotherapy]. Magy Onkol. 2006;50(1):33-7. Epub 2006 Apr 17.
6 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
7 Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:117-20.
8 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
9 Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab Dispos. 2005 Sep;33(9):1361-6. doi: 10.1124/dmd.105.004796. Epub 2005 Jun 24.
10 Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. J Surg Oncol. 2008 Aug 1;98(2):130-4.
11 Dependence of chemotherapy response on p53 mutation status in a panel of human cancer lines maintained in nude mice. Cancer Sci. 2004 Jun;95(6):541-6. doi: 10.1111/j.1349-7006.2004.tb03246.x.
12 Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
13 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
14 Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro. 2008 Dec;22(8):1846-52.
15 Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
16 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
17 Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23.
18 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
19 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
20 Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2012 Jun 1;118(11):2828-36. doi: 10.1002/cncr.26614. Epub 2011 Oct 21.